GSK221149A

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Obstetric Labour, PrematurePremature Labor

Phase 1

Absorption, Distribution, Metabolism And Excretion Study For GSK221149A

CompletedNCT00457925

GlaxoSmithKlineObstetric Labour, Premature, Premature Labor

Start: 2006-10-31Target: 6Updated: 2012-03-19

Phase 2

The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor

CompletedNCT00404768

GlaxoSmithKlineObstetric Labour, Premature

Start: 2007-10-12End: 2011-07-07Updated: 2018-01-16